Share

Today, we would like to share with you the talk given by Kelsey Moody, CEO of Biotech Company Ichor, at the recent Ending Age-Related Diseases: Investment Prospects & Advances in Research conference in New York City. In this talk, Kelsey discusses Ichor’s protein engineering platform, how Ichor has used it, and Ichor’s plans for using it to discover new classes of drugs for age-related diseases.

Kelsey is a process-oriented biotechnology executive who has specialized in the study of aging and aging mechanisms for over a decade. Since 2013, he has successfully built Ichor Therapeutics from a living room start-up into a premier, vertically integrated contract research organization that focuses on preclinical research services for aging pathways. Proceeds from this work are used to self-fund R&D initiatives that constitute Ichor’s portfolio companies in enzyme therapy (Lysoclear, Inc.), small molecule drug discovery (Antoxerene, Inc.), and protein engineering (RecombiPure, Inc.) Kelsey has received graduate-level training in medicine, business, and laboratory research.

Kelsey is very much a rising star in the field, and we suspect that he may become one of the most important people in the development of therapies in the next few years, judging by his impressive track record to date. We are watching the work that Ichor and its portfolio companies are doing with great interest, and we are grateful to Kelsey for giving this talk, for sponsoring the conference, and for continuing to be a driving force for progress against age-related diseases.

About the author

Steve Hill

Steve serves on the LEAF Board of Directors and is the Editor in Chief, coordinating the daily news articles and social media content of the organization. He is an active journalist in the aging research and biotechnology field and has to date written over 500 articles on the topic as well as attending various medical industry conferences. In 2019 he was listed in the top 100 journalists covering biomedicine and longevity research in the industry report – Top-100 Journalists covering advanced biomedicine and longevity created by the Aging Analytics Agency. His work has been featured in H+ magazine, Psychology Today, Singularity Weblog, Standpoint Magazine, and, Keep me Prime, and New Economy Magazine. Steve has a background in project management and administration which has helped him to build a united team for effective fundraising and content creation, while his additional knowledge of biology and statistical data analysis allows him to carefully assess and coordinate the scientific groups involved in the project. In 2015 he led the Major Mouse Testing Program (MMTP) for the International Longevity Alliance and in 2016 helped the team of the SENS Research Foundation to reach their goal for the OncoSENS campaign for cancer research.
  1. August 21, 2018

    I think a huge market could be a topical RPTag to il4r which is targeted by Sanofi’s Durpexent antibody for eczema.

Write a comment:

*

Your email address will not be published.

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD